ZymoGenetics

  www.zymogenetics.com
  www.zymogenetics.com
Work in HR? Unlock Free Profile

ZymoGenetics Reviews

12 Reviews
3.7
12 Reviews
Rating Trends

Recommend to a friend
Approve of CEO
(no image)
Jeremy Levin
0 Ratings
  1.  

    A wonderful place to work-forming a new identity post- BMS!

    • Comp & Benefits
    • Work/Life Balance
    • Senior Management
    • Culture & Values
    • Career Opportunities
    Current Employee - Anonymous Employee
    Current Employee - Anonymous Employee

    I have been working at ZymoGenetics

    Pros

    -Relaxed Biotech Culture
    -Fabulous People
    -Contribute to something great!

    Cons

    -Lots of shifts as the site finds its identity w/in BMS

    Recommends
    No opinion of CEO

ZymoGenetics Interviews

Interview Experience

Interview Experience

100%
0%
0%

Getting an Interview

Getting an Interview

50%
50%

Interview Difficulty

3.0
Average

Interview Difficulty

Hard

Average

Easy
  1.  

    Scientist Interview

    Anonymous Interview Candidate  in  Seattle, WA
    Anonymous Interview Candidate in Seattle, WA
    Application Details

    I applied through an employee referral - interviewed at ZymoGenetics.

    Interview Details

    Pretty straightforward - seminar, 1:1 with other scientists

    Interview Questions
    Accepted Offer
    Positive Experience
    Average Interview

ZymoGenetics Awards & Accolades

Let us know if we're missing any workplace or industry recognition – Add an award

Additional Info

Unlock Profile
Website www.zymogenetics.com
Headquarters Seattle, WA
Size 150 to 499 Employees
Founded 1981
Type Subsidiary or Business Segment
Industry Biotech & Pharmaceuticals
Revenue Unknown / Non-Applicable per year
Competitors Baxter, Pfizer, Ethicon

ZymoGenetics has proteins on its plate. The firm culls genomics databases to indentify and develop protein-based drugs targeting a variety conditions. Its sole commercial product, RECOTHROM (rThrombin), controls bleeding during surgery. Unlike existing forms of thrombin, RECOTHROM is derived from recombinant proteins instead of animal or human blood, which can trigger adverse reactions. The lead candidate in ZymoGenetics' research and development pipeline is an antiviral therapy to treat hepatitis C. The company is a wholly owned subsidiary of Bristol-Myers Squibb (BMS).

Worked for ZymoGenetics? Contribute to the Community!